Accelerated Biosciences and Stemmatters announced their strategic partnership aimed at co-developing and co-marketing human induced pluripotent stem cells (“iPSC”) derived from human trophoblast stem cells (“hTSC”). By utilizing Accelerated Bio’s innovative hTSC platform, this partnership seeks to deliver iPSC derived from the earliest-stage material, creating an optimal foundation for regenerative medicine. This partnership marks Accelerated Biosciences’ entry into the EU market, broadening its reach and bringing its cutting-edge hTSC technology to a new geographic region with extensive potential for regenerative therapies.
Rui A. Sousa, CEO of Stemmatters, expressed his enthusiasm for the collaboration: "We recognize the immense potential of hTSC as a groundbreaking platform for scalable manufacturing of multiple cell types, including iPSCs. This technology enhances our value proposition and strengthens our commitment to advancing cell therapy and regenerative medicine development in Europe."
Yuta Lee, CEO of Accelerated Bio, emphasized the advanced capabilities of the hTSC platform: "Our hTSC platform is not only the earliest ethically sourced pluripotent stem cell source available but also one of the most dynamic and versatile. This collaboration with Stemmatters will enhance our understanding of hTSC characteristics and enable us to develop the necessary tools and knowledge to engineer and optimize hTSC to iPSC reprogramming processes to create a better iPSC platform for regenerative medicine."
Through this partnership, Stemmatters and Accelerated Bio aim to establish capabilities to develop and manufacture hTSC-derived iPSC compliant with EU regulatory requirements, offering this superior iPSC platform to European community and developing new treatment options to patients.